<DOC>
	<DOCNO>NCT00096057</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody HuHMFG1 locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : This phase I trial study side effect best dose monoclonal antibody HuHMFG1 treat woman locally advance metastatic breast cancer .</brief_summary>
	<brief_title>Monoclonal Antibody HuHMFG1 Treating Women With Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety tolerability monoclonal antibody HuHMFG1 woman locally advance metastatic breast cancer . - Determine safe recommend dose schedule drug patient . - Determine pharmacokinetic profile , absence chemotherapy endocrine agent , drug patient . - Determine antitumor activity drug patient . - Determine time progression patient treat drug . - Assess immunological marker ( e.g. , granzyme B , gamma interferon , C1Q ) determine response drug patient . - Assess marker immunogenicity ( e.g. , human anti-human antibody ) drug patient . - Assess tumor marker ( e.g. , CA15.3 CEA ) patient treat drug . - Correlate , preliminarily , soluble HMFG1 antigen level pharmacokinetic data drug patient . OUTLINE : This open-label , non-randomized , dose-escalation study . Patients cohorts 1 2 receive monoclonal antibody HuHMFG1 IV 1-3 hour every 21 day dose 1 2 . All subsequent dose interval base individual half-life value drug , within 3 day estimate half-life multiple 7 day . Patients cohorts 3 4 receive monoclonal antibody HuHMFG1 dose interval determine first 2 cohort . Treatment continue absence disease progression unacceptable toxicity . Cohorts 6 patient receive escalate dos monoclonal antibody HuHMFG1 maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 6 patient experience dose-limiting toxicity . All patient follow 4 week every 6 week 6 month . Patients antitumor response stable disease follow every 12 week disease progression initiation another antitumor treatment . PROJECTED ACCRUAL : A total 6-24 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm breast cancer Locally advance metastatic disease No inflammatory breast cancer Measurable ( RECIST ) evaluable disease ( e.g. , cytologically radiologically detectable disease fulfill RECIST criterion ) Failed prior OR candidate OR refuse anthracycline taxanecontaining chemotherapy Patients whose tumor overexpresses HER2 must fail prior trastuzumab ( Herceptin® ) No know CNS metastases No metastasis accessible complete surgical resection Unstained slide cut formalinfixed paraffinembedded tumor block available Appropriate tumor block also acceptable Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Female Menopausal status Not specify Performance status WHO 01 Life expectancy At least 4 month Hematopoietic Hemoglobin ≥ 10 g/dL Absolute neutrophil count ≥ 1,500/mm^3 WBC ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 1.5 mg/dL ALT AST ≤ 2.5 time upper limit normal ( ULN ) ( &lt; 5 time ULN patient liver metastasis ) OR Alkaline phosphatase ≤ 2.5 time ULN ( &lt; 5 time ULN patient liver metastasis ) Any degree elevate alkaline phosphatase allow provide due bone metastases Renal Creatinine ≤ 1.5 time ULN OR Creatinine clearance &gt; 60 mL/min Uric acid &lt; 1.25 time ULN ( patient hyperuricemia ) Calcium ( correct serum albumin ) &lt; 11.5 mg/dL ( patient hypercalcemia ) Cardiovascular LVEF ≥ 45 % MUGA echocardiogram within past 4 week Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception No malignancy within past 5 year except adequately treat nonmelanoma skin cancer cervical intraepithelial neoplasia No uncontrolled illness would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Prior biological therapy allow More 2 week since prior blood transfusion growth factor aid hematological recovery No concurrent antitumor immunotherapy Chemotherapy See Disease Characteristics More 4 week since prior cytotoxic chemotherapy No 3 prior chemotherapy regimen , include adjuvant/neoadjuvant therapy No concurrent antitumor chemotherapy Endocrine therapy Prior hormonal therapy allow No concurrent corticosteroid except physiologic replacement and/or acute shortterm treatment , prophylaxis , infusion reaction No concurrent antitumor hormonal therapy Radiotherapy See Disease Characteristics More 4 week since prior radiotherapy ( except palliative radiotherapy ) No concurrent antitumor radiotherapy , except palliation nonstudy lesion Irradiated area small possible involve ≤ 10 % bone marrow give 4week period Surgery More 4 week since prior major surgery Other More 30 day since prior investigational agent No concurrent investigational agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>